TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01202890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid, Doxil, Avastin
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
Study: NCT02242058

Intervention type: OTHER
Intervention: Quantitative sensory testing

Intervention type: OTHER
Intervention: Quantitative sensory testing

Intervention type: OTHER
Intervention: Quantitative sensory testing

Intervention type: OTHER
Intervention: Quantitative sensory testing

Intervention type: OTHER
Intervention: Quantitative sensory testing
Study: NCT03159468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Description: Participants consume an alcoholic beverage in the lab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Description: Participants consume an alcoholic beverage in the lab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Description: Participants consume an alcoholic beverage in the lab.
Study: NCT02377414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban solution for Infusion
Description: Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban solution for Infusion
Description: Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
Study: NCT02106182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-days voiding diary
Description: 3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 weeks
Study: NCT00936663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Study: NCT01769976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic fasting
Study: NCT04255277

Intervention type: DRUG
Group type: OTHER
Intervention: Cenerimod 4 mg
Description: This will be administered orally as a film-coated tablet in the morning.
Study: NCT02077920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
Study: NCT04255277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Description: This will be administered orally as a film-coated tablet in the morning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal, activated
Description: Granules for oral suspension will be used and administered open-label.
Study: NCT02077920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Description: Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber bronchoscope
Description: For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
Study: NCT04786145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis
Description: This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No active treatment is given.
Study: NCT01382212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
Study: NCT02840500

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04002661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flibanserin
Description: Flibanserin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT00743483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBSSL
Description: oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
Study: NCT03017495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg/mL oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Hard gelatin capsules for oral use at a strength of 25 mg
Study: NCT01769976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction
Study: NCT04255277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal, activated
Description: Granules for oral suspension will be used and administered open-label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Study: NCT01769976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy balance diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy balance diet
Study: NCT01503814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular disease management
Description: This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)
Study: NCT04357184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
Study: NCT03076281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin +Doxycycline
Description: Given orally
Study: NCT04045782

Intervention type: DRUG
Group type: OTHER
Intervention: single arm
Description: switch from originator (Humira) to biosimilar (Imraldi)
Study: NCT03266081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Description: topical anesthetic
Study: NCT01426698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed cord clamping
Description: at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
Study: NCT00894543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
Study: NCT02622568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veregen only
Description: Topical application of Veregen 15% ointment on affected areas twice daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy and Veregen
Description: Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
Study: NCT03425552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
Study: NCT04011592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Description: single intravenous infusion of Ketamine (0.5 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Description: single intravenous infusion of Ketamine (0.5 mg/kg)
Study: NCT04426994

Intervention type: DRUG
Intervention: proton pump inhibitor use
Description: Patients using long term proton pump inhibitor

Intervention type: DRUG
Intervention: proton pump inhibitor use
Description: Patients using long term proton pump inhibitor
Study: NCT04011592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Description: single intravenous infusion of Ketamine (0.2 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Description: single intravenous infusion of Ketamine (0.2 mg/kg)
Study: NCT03425552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
Study: NCT03210896

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Sub group I will drink Orange juice and have repeat measures.
Study: NCT02390570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Capacity Assessment Instrument
Description: The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
Study: NCT03470376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC)
Description: An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No nutraceutical combination (noNC)
Description: Prosecution of standardized diet regimen for 3 months
Study: NCT02492516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: mesenchymal stem cells injection via peripheral vein.
Study: NCT01970813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture and bee venom acupuncture point injection
Description: acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture and normal saline injections
Description: sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
Study: NCT02515071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study: NCT01957852

Intervention type: OTHER
Intervention: FloSeal
Study: NCT00884221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly purified menotrophin
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FSH
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Study: NCT02748122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MMT 723
Description: Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
Study: NCT01993056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA 11+

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: no FIFA 11+
Study: NCT03032510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Study: NCT05558488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meatless, restrictive ketogenic diet
Description: Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes.
Study: NCT02126046

Intervention type: GENETIC
Group type: OTHER
Intervention: unrelated CB following haplo-identical hematopoietic stem cells transplantation
Study: NCT03032510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study: NCT01371526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot tetracosactide
Description: 1mg, 3x weekly by sc injection
Study: NCT02773056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ischial Ramus Containment (IRC)
Description: Ischial Ramus Containment (IRC) is the standard of care socket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Socket Ischial Ramus Containment (IRC)
Description: Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Ischial Interface (Sub-I)
Description: Sub-Ischial Interface (Sub-I) is a comparator study socket
Study: NCT00806078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324 mg capsules (648 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324 mg capsules (648 mg)
Study: NCT00547898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg
Description: Crofelemer 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 250 mg
Description: Crofelemer 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 500 mg
Description: Crofelemer 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03040817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric peroral endoscopic pyloromyotomy (G-POEM)
Description: G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole + Mosapride
Description: Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
Study: NCT01768338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab combined with SB-485232
Description: Ofatumumab with escalating doses of SB-485232
Study: NCT03433144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Description: An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.